Literature DB >> 10193491

Spinal cord injuries in adolescents after gunshot wounds: an increasing phenomenon in urban North America.

E H Carrillo1, J K Gonzalez, L E Carrillo, P M Chacon, N Namias, O C Kirton, P M Byers.   

Abstract

While much attention is focused on firearm fatalities, the purpose of this study was to determine the expense of acute medical care and the rehabilitation experience of surviving adolescent patients in the USA with spinal cord injury secondary to gunshot wounds. We analyzed a cohort of 19 patients, 18 of whom survived 12 months after spinal cord injury. The need for primary medical care related to the injury, current work and scholastic status, and satisfaction with the quality of rehabilitation were determined. Ten were not involved in any type of academic or meaningful activity, five had returned to school, three were undergoing rehabilitation, and one patient died. Major complications were present in 14 of the 18 patients. Thus, despite a high survival rate after spinal cord injury in this USA population, considerable long-term disability persists, and survivors report a low level of satisfaction with life.

Entities:  

Mesh:

Year:  1998        PMID: 10193491     DOI: 10.1016/s0020-1383(98)00110-7

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  3 in total

1.  Gunshot Injuries in Lebanon: Does Intent Affect Characteristics, Injury Patterns, and Outcomes in Victims?

Authors:  Hady Zgheib; Sami Shayya; Cynthia Wakil; Rana Bachir; Mazen J El Sayed
Journal:  J Emerg Trauma Shock       Date:  2019 Apr-Jun

2.  Spinal Injury Associated With Firearm Use.

Authors:  Randall T Loder; Abhipri Mishra; Bradley Atoa; Allison Young
Journal:  Cureus       Date:  2021-03-16

Review 3.  Pediatric arrowshot injury to cervical spinal cord-sagittal cord transection with no neurological deficit and good outcome: case report and review of literature.

Authors:  Tymon Skadorwa; Bogdan Ciszek
Journal:  Childs Nerv Syst       Date:  2013-04-12       Impact factor: 1.475

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.